NEW YORK, June 18 – In another move towards entering the diagnostics market, Pyrosequencing said Monday it had signed a research agreement with The Children’s Hospital of Philadelphia to analyze genes associated with deafness.
Pyrosequencing, of Uppsala, Sweden, which initially positioned its sequencing technology to exploit the research market, has said repeatedly that it is hoping to develop diagnostic products. Last month, the company said it had been awarded a patent for applying its technology to assessing cardiovascular conditions such as myocardial infarction and stroke.
The agreement with The Children’s Hospital of Philadelphia (CHOP) will target the Connexin 26 gene, a gene with mutations associated with 65 percent of autosomal recessive non-syndromic hearing loss. Researchers at the Molecular Diagnostics Laboratory at CHOP will use Pyrosequencing’s sequencing technology to screen patients with this type of deafness to analyze mutations in the Connexin 26 gene.
The team at CHOP will also screen patients for a genetic mutation associated with hearing loss in children treated with aminoglyside antibiotics, the company said.
“Our research project with The Children's Hospital of Philadelphia demonstrates the interest that the molecular diagnostic community has in our DNA analysis solutions and our commitment to developing clinical applications of our technology," Erik Wallden, CEO of Pyrosequencing, said in a statement.